Polycystic Kidney Disease

Polycystic kidney disease (PKD) is a hereditary, progressive disorder characterized by the development of multiple fluid-filled cysts within the renal parenchyma, leading to gradual destruction of functional renal tissue and eventual end-stage renal failure. In veterinary medicine, the most recognized form is autosomal dominant polycystic kidney disease (ADPKD) in Persian and related cat breeds, caused by a mutation in the PKD1 gene. The disease is bilateral and diffuse, with cysts arising from tubular epithelial cells, particularly the proximal tubules and collecting ducts. As cysts enlarge, they compress adjacent parenchyma, causing ischemia, inflammation, and fibrosis, ultimately resulting in chronic kidney disease (CKD). The condition is progressive, with clinical signs typically manifesting in middle-aged to older animals, although early-onset cases can occur. PKD is a significant cause of morbidity and mortality in affected breeds, and early diagnosis is crucial for management and breeding decisions.

The primary etiology of polycystic kidney disease in cats is an autosomal dominant mutation in the PKD1 gene, which encodes polycystin-1, a protein involved in ciliary function and tubular cell differentiation. The specific mutation, a C-to-A transversion in exon 29, leads to a premature stop codon and a truncated nonfunctional protein. This mutation is inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is sufficient to cause the disease. In dogs, PKD is rare but has been reported in certain breeds, such as Bull Terriers and West Highland White Terriers, with a possible autosomal recessive inheritance in some cases. The exact genetic mutations in dogs are less well characterized. Other potential causes of renal cyst formation include acquired conditions such as chronic renal failure, but true polycystic disease is primarily genetic. No infectious, toxic, or environmental agents have been identified as primary causes of PKD in domestic animals.

Polycystic kidney disease is most prevalent in Persian cats and related breeds, including Himalayans and Exotic Shorthairs. Studies have reported a prevalence of 36-49% in Persian cats in various countries, with a global distribution. The disease is also seen in other breeds with Persian lineage. In dogs, PKD is uncommon, but cases have been documented in Bull Terriers, Cairn Terriers, and West Highland White Terriers. There is no sex predilection, as the inheritance is autosomal. The age of onset of clinical signs typically ranges from 3 to 10 years, with a mean around 7 years, but cysts can be detected as early as 6-8 months of age via ultrasound. The disease is progressive, and most affected cats develop chronic kidney disease by middle age. Geographic variation is minimal, but the prevalence is higher in catteries where affected breeding cats are used. The condition is a major concern in feline breeding programs, and genetic screening is recommended.

The pathophysiology of PKD begins with the genetic mutation leading to abnormal ciliary function in renal tubular epithelial cells. Polycystin-1 and polycystin-2 form a complex that regulates intracellular calcium signaling and cell proliferation. The defective protein disrupts this signaling, leading to uncontrolled cell proliferation and fluid secretion, resulting in cyst formation. Cysts arise from various nephron segments, but predominantly from the collecting ducts and distal tubules. Initially, cysts are microscopic and do not affect renal function. As they enlarge, they compress adjacent renal parenchyma, causing ischemia, tubular obstruction, and interstitial inflammation. The release of inflammatory mediators and growth factors promotes fibrosis, further reducing functional nephron mass. Over time, the kidneys become enlarged and irregular, with a marked reduction in glomerular filtration rate (GFR). The compensatory hyperfiltration in remaining nephrons accelerates glomerulosclerosis, leading to a vicious cycle of progressive renal damage. Systemic complications include hypertension, which develops in up to 50% of affected cats, and secondary hyperparathyroidism due to phosphate retention and decreased calcitriol production. The end-stage is uremia, with multiple organ system involvement.

The primary predisposing factor for PKD is genetic inheritance, specifically the presence of the PKD1 mutation. Cats with a family history of PKD are at high risk. Breed predisposition is significant, with Persian and Persian-cross cats being most susceptible. Age is a factor, as the disease progresses over time, and clinical signs typically appear in middle age. There is no sex predilection. Environmental factors such as diet and management do not cause the disease but may influence the rate of progression. For example, diets high in protein and phosphorus may exacerbate renal damage. Concurrent conditions such as urinary tract infections or urolithiasis can accelerate the decline in renal function. In dogs, the genetic basis is less clear, but a familial pattern is observed in Bull Terriers. Early detection through genetic testing and ultrasound screening is crucial to prevent propagation of the disease in breeding populations.

Clinical signs of PKD are related to progressive chronic kidney disease and may not appear until significant renal function is lost (typically >75% of nephrons are nonfunctional). Early signs are subtle and include polyuria, polydipsia, and intermittent inappetence. As the disease progresses, more obvious signs develop: weight loss, lethargy, vomiting, diarrhea, and poor coat condition. In advanced stages, signs of uremia include oral ulceration, uremic breath, anemia, and neurological signs such as depression, weakness, and seizures. Hypertension may be present, leading to retinal detachment or blindness, and cardiac murmurs due to left ventricular hypertrophy. On physical examination, palpation of the kidneys may reveal irregular, enlarged kidneys, especially in advanced cases. Some cats may present with hematuria or urinary tract infections. In dogs, clinical signs are similar, but the age of onset may be earlier in some breeds. The disease is bilateral, but the rate of progression can vary between individuals.

Differential diagnoses for polycystic kidney disease include other causes of renomegaly and chronic kidney disease. Key differentials are: 1) Chronic interstitial nephritis (CIN) – a common cause of CKD in cats, but kidneys are typically small and irregular, not enlarged with cysts. 2) Renal lymphoma – can cause renomegaly, but ultrasound shows diffuse hypoechogenicity or mass lesions, not discrete cysts. 3) Renal neoplasia (e.g., renal adenocarcinoma) – usually unilateral, with a solid mass on imaging. 4) Hydronephrosis – due to ureteral obstruction, resulting in a dilated renal pelvis, not multiple cortical cysts. 5) Perinephric pseudocysts – fluid accumulation around the kidney, but the renal parenchyma is normal. 6) Renal cysts associated with chronic renal failure – can occur but are usually few and not as numerous as in PKD. 7) Amyloidosis – causes renomegaly but with a characteristic echogenicity and no cysts. 8) Feline infectious peritonitis (FIP) – can cause renomegaly and granulomatous lesions, but systemic signs and other organ involvement are present. Definitive diagnosis of PKD is based on genetic testing or characteristic ultrasound findings.

The diagnostic approach for PKD begins with a thorough history and physical examination, with attention to breed and family history. If PKD is suspected, the following steps are recommended: 1) Baseline blood work (CBC, serum biochemistry, including renal parameters and electrolytes) and urinalysis to assess renal function and rule out other causes. 2) Abdominal ultrasound is the primary imaging modality; it is highly sensitive and specific for detecting renal cysts. In cats, the presence of at least two cysts in one kidney or one cyst in each kidney, in a breed predisposed to PKD, is considered diagnostic. Ultrasound can detect cysts as small as 2 mm. 3) Genetic testing (PCR-based assay for the PKD1 mutation) is available for cats and can confirm the diagnosis, especially in young animals or when ultrasound findings are equivocal. 4) If ultrasound is inconclusive, advanced imaging such as CT or MRI may be used, but they are rarely necessary. 5) In breeding programs, genetic testing is recommended before breeding to identify carriers. 6) Renal biopsy is generally not indicated for diagnosis but may be performed if there is suspicion of concurrent disease. The algorithm emphasizes early screening in at-risk breeds, as early detection allows for management and breeding decisions.

Laboratory findings in PKD reflect progressive chronic kidney disease. In early stages, blood work may be normal. As the disease advances, azotemia develops (elevated BUN and creatinine). Serum creatinine is a reliable indicator of renal function, but it only increases after significant loss of nephrons. SDMA (symmetric dimethylarginine) is an earlier biomarker of renal dysfunction and may be elevated before creatinine. Hyperphosphatemia is common, and calcium-phosphorus product may be elevated. Metabolic acidosis may be present due to decreased renal excretion of hydrogen ions. Anemia is common in advanced CKD due to decreased erythropoietin production. Urinalysis typically shows isosthenuria (urine specific gravity <1.030 in cats, <1.020 in dogs) and may reveal proteinuria (urine protein:creatinine ratio >0.4 in cats). Hematuria and pyuria may be present if there is a concurrent urinary tract infection. Blood pressure measurement is essential, as hypertension is common. In some cases, hyperkalemia may occur in end-stage disease. Genetic testing (PCR) for the PKD1 mutation is confirmatory in cats.

Imaging is central to the diagnosis of PKD. Abdominal radiography may show renomegaly with irregular contours, but it is not sensitive for cyst detection. Ultrasonography is the modality of choice. In affected cats, ultrasound reveals multiple anechoic, thin-walled cysts of varying sizes distributed throughout the renal cortex and medulla. The kidneys are typically enlarged and irregular. Cysts may be present in other organs, such as the liver (hepatic cysts) and pancreas, though less commonly. Doppler ultrasound can assess renal blood flow, which may be reduced in advanced disease. Computed tomography (CT) and magnetic resonance imaging (MRI) provide detailed anatomical information and can detect smaller cysts, but they are not routinely used due to cost and the need for anesthesia. In dogs, ultrasound findings are similar. Advanced imaging may be useful for surgical planning if cyst decompression is considered, but this is rarely performed. Ultrasound is also used for screening at-risk breeds, and it is recommended that Persian cats be screened annually from 6 months of age.

Cytology and histopathology are not typically required for diagnosis of PKD, as imaging and genetic testing are sufficient. However, if a renal biopsy is performed (e.g., to rule out concurrent disease), histopathology will show multiple cysts lined by cuboidal to flattened epithelium, with variable amounts of interstitial fibrosis and inflammation. The cysts are filled with clear fluid, and the surrounding parenchyma shows compression atrophy, glomerulosclerosis, and tubular atrophy. Special stains may be used to identify the epithelial origin, but this is not necessary for diagnosis. In cases where a cyst is aspirated, the fluid is typically clear and acellular, consistent with a transudate. Cytology of the fluid is not diagnostic. Histopathology is more useful for research purposes or to confirm the extent of renal damage. In breeding programs, genetic testing is preferred over biopsy for diagnosis.

There is no cure for PKD, and treatment is aimed at managing chronic kidney disease and its complications. The goals are to slow disease progression, manage clinical signs, and maintain quality of life. The following strategies are recommended: 1) Dietary management: A renal diet low in protein, phosphorus, and sodium, and supplemented with omega-3 fatty acids, is recommended for cats with IRIS stage 2-4 CKD. These diets help reduce azotemia, hyperphosphatemia, and hypertension. 2) Hydration: Encourage water intake by providing fresh water, wet food, or subcutaneous fluids (e.g., 20-30 ml/kg every 24-48 hours) if dehydration is present. 3) Phosphate binders: If hyperphosphatemia persists despite dietary restriction, administer phosphate binders such as aluminum hydroxide (30-100 mg/kg/day PO divided with meals) or calcium acetate (60-90 mg/kg/day PO). 4) Antihypertensive therapy: If systolic blood pressure >160 mmHg, treat with amlodipine (0.625-1.25 mg/cat PO q24h) or benazepril (0.25-0.5 mg/kg PO q24h). 5) Management of proteinuria: If UPC >0.4, consider ACE inhibitors (benazepril or enalapril at 0.25-0.5 mg/kg PO q24h). 6) Treatment of anemia: If PCV <20%, consider erythropoietin therapy (100 IU/kg SC three times weekly) or blood transfusion in severe cases. 7) Management of uremic signs: Antiemetics (maropitant 1 mg/kg SC q24h), antacids (famotidine 0.5 mg/kg PO q12h), and appetite stimulants (mirtazapine 1.88 mg/cat PO q48h). 8) Surgical intervention: In rare cases, cyst decompression or nephrectomy may be considered for pain or if a cyst becomes infected, but this is not routinely recommended. 9) Genetic counseling: Affected cats should not be bred.

The prognosis for PKD is guarded to poor, as the disease is progressive and ultimately fatal. The rate of progression varies among individuals. Some cats may live for years with good quality of life if managed appropriately, while others may progress rapidly to end-stage renal failure. The median survival time after diagnosis is approximately 2-3 years, but this can be longer with early detection and aggressive management. Negative prognostic indicators include: early onset of clinical signs (before 3 years of age), severe azotemia at diagnosis (IRIS stage 3 or 4), presence of hypertension, proteinuria, and anemia. Cats that respond well to dietary and medical management may have a better prognosis. In dogs, the prognosis is similarly poor, but data are limited. Regular monitoring and proactive management can extend survival and improve quality of life. Ultimately, most affected animals are euthanized due to end-stage renal failure.

Follow-up for PKD involves regular monitoring of renal function and blood pressure. For cats with IRIS stage 1 or 2 CKD, recheck every 3-6 months. For stage 3 or 4, recheck every 1-3 months. At each visit, perform a physical examination, body weight, blood pressure measurement, serum biochemistry (including creatinine, BUN, phosphorus, potassium, and SDMA), and urinalysis. Urine protein:creatinine ratio should be assessed periodically. Imaging (ultrasound) may be repeated annually to monitor cyst growth, but it is not essential for management. Adjust medications based on laboratory results. For example, phosphate binders should be titrated to maintain serum phosphorus within the target range (IRIS guidelines: <4.5 mg/dL for stage 2, <5.0 mg/dL for stage 3, <6.0 mg/dL for stage 4). Blood pressure should be maintained below 160 mmHg. Owners should be educated on signs of uremia and dehydration. Genetic testing of related animals is recommended to prevent further spread of the disease.

Pearls: 1) In Persian cats, the presence of even a single renal cyst on ultrasound is highly suggestive of PKD, but a definitive diagnosis requires genetic testing or the presence of multiple cysts. 2) Early screening of at-risk breeds is essential; ultrasound can detect cysts as early as 6-8 months of age. 3) Hypertension is common in PKD, so blood pressure should be measured at every visit. 4) Dietary management is the cornerstone of treatment; a renal diet can significantly slow disease progression. 5) SDMA is a more sensitive marker of early renal dysfunction than creatinine. Pitfalls: 1) Do not rely solely on palpation for diagnosis, as kidneys may not be enlarged in early stages. 2) Avoid using NSAIDs or other nephrotoxic drugs in affected animals. 3) Do not overlook concurrent urinary tract infections, which can accelerate renal damage. 4) Do not delay treatment until azotemia is present; early intervention is key. 5) Do not breed affected animals or their parents, as the disease is inherited.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used in managing PKD and its complications: 1) Amlodipine besylate: For hypertension, 0.625-1.25 mg/cat PO q24h, titrate to effect. In dogs, 0.05-0.1 mg/kg PO q24h. 2) Benazepril hydrochloride: For proteinuria and hypertension, 0.25-0.5 mg/kg PO q24h in cats and dogs. 3) Enalapril: Alternative ACE inhibitor, 0.25-0.5 mg/kg PO q12-24h. 4) Aluminum hydroxide: As a phosphate binder, 30-100 mg/kg/day PO divided with meals. 5) Calcium acetate: 60-90 mg/kg/day PO divided with meals. 6) Maropitant citrate: For vomiting, 1 mg/kg SC q24h or 2 mg/kg PO q24h. 7) Famotidine: For gastric ulceration, 0.5 mg/kg PO/IV q12-24h. 8) Mirtazapine: As an appetite stimulant, 1.88 mg/cat PO q48h. 9) Erythropoietin: For anemia, 100 IU/kg SC three times weekly, monitor PCV. 10) Subcutaneous fluids: 20-30 ml/kg of lactated Ringer's or 0.9% saline, administered as needed. All dosages should be adjusted based on renal function, and caution is advised with drugs that are renally excreted. Drug interactions should be considered, especially with ACE inhibitors and potassium-sparing diuretics.

The literature on PKD in veterinary medicine is primarily focused on feline ADPKD. A landmark study by Barrs et al. (2001) established the prevalence of PKD in Persian cats in Australia and validated ultrasound as a diagnostic tool. Subsequent studies have confirmed the genetic basis, with the PKD1 mutation identified by Lyons et al. (2004). The ACVIM consensus statement on CKD (2019) provides guidelines for management, including the use of renal diets, blood pressure control, and proteinuria management. IRIS (International Renal Interest Society) staging guidelines are widely used for treatment decisions. Studies have shown that early dietary intervention can slow disease progression. A study by King et al. (2007) demonstrated that a renal diet improved survival in cats with CKD. Regarding hypertension, a study by Jepson et al. (2007) showed that amlodipine is effective in reducing blood pressure in cats. There is limited literature on PKD in dogs, but case reports exist. Overall, the evidence supports early screening, genetic testing, and aggressive management of CKD to improve outcomes.